CDK4 is an essential insulin effector in adipocytes
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Insulin resistance is a fundamental pathogenic factor that characterizes various metabolic disorders, including obesity and type 2 diabetes. Adipose tissue contributes to the development of obesity-related insulin resistance through increased release of fatty acids, altered adipokine secretion, and/or macrophage infiltration and cytokine release. Here, we aimed to analyze the participation of the cyclin-dependent kinase 4 (CDK4) in adipose tissue biology. We determined that white adipose tissue (WAT) from CDK4-deficient mice exhibits impaired lipogenesis and increased lipolysis. Conversely, lipolysis was decreased and lipogenesis was increased in mice expressing a mutant hyperactive form of CDK4 (CDK4(R24C)). A global kinome analysis of CDK4-deficient mice following insulin stimulation revealed that insulin signaling is impaired in these animals. We determined that insulin activates the CCND3-CDK4 complex, which in turn phosphorylates insulin receptor substrate 2 (IRS2) at serine 388, thereby creating a positive feedback loop that maintains adipocyte insulin signaling. Furthermore, we found that CCND3 expression and IRS2 serine 388 phosphorylation are increased in human obese subjects. Together, our results demonstrate that CDK4 is a major regulator of insulin signaling in WAT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Insulin signalling and the regulation of glucose and lipid metabolism
Saltiel, A. R., & Kahn, C. R. (2001) · Nature · doi:10.1038/414799a · Cited by 5,326 · cited 2×
“org Volume 126 Number 1 January 2016 Introduction Insulin signaling is a versatile system that coordinates growth, proliferation, and development of multiple tissues and organs by controlling metabolic processes that accommodate the energy needs of cellular function (1).”
BackgroundSelf-citationCell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 1×
“Many studies have assessed the roles of CDK4 in cell growth, proliferation, and cancer (10), but the role of CDK4 in adipose tissue function has never been explored.”
BackgroundA new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650 · cited 1×
“β Cell– specific reexpression of the Cdk4R24C allele renders CDK4 resistant to the inhibitory effects of INK4 proteins (12) and restores β cell proliferation and normoglycemic conditions (13).”
BackgroundFatty acid synthase and the lipogenic phenotype in cancer pathogenesis
Menendez, J. A., & Lupu, R. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2222 · Cited by 2,941 · cited 1×
“Interestingly, it has previously been reported that a major enzyme of de novo lipogenesis, the fatty acid synthase (FASN), is increased in numerous cancers, including breast cancer (35).”
BackgroundThe history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Palbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · cited 8×
“The CDK4/ CDK6 inhibitor (PD0332991, palbociclib) has been approved for the treatment of breast cancer (33).”
BackgroundInfluentialCopps, K. D., & White, M. F. (2012) · Diabetologia · doi:10.1007/s00125-012-2644-8 · Cited by 1,017 · cited 1×
“Both positive and negative phosphorylation sites finely regulate IRS1 and IRS2 activity and are a paradigm of the flexibility of insulin and IGF signaling (36).”
BackgroundMatsushime, H., Ewen, M. E., Strom, D. K., Kato, J.-Y., Hanks, S. K., Roussel, M. F., & Sherr, C. J. (1992) · Cell · doi:10.1016/0092-8674(92)90360-o · Cited by 897
Insulin signaling in health and disease
White, M. F. (2003) · Science · doi:10.1126/science.1092952 · Cited by 733 · cited 1×
“Defects in insulin signaling contribute to insulin resistance, a common complication of obesity that occurs early in the pathogenesis of type 2 diabetes and cardiovascular disease (2, 3).”
Background
Cited by
Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028
CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest
Goel, S., DeCristo, M. J., McAllister, S. S., & Zhao, J. J. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.07.002 · Cited by 501
Metabolic reprogramming in cancer: Mechanisms and therapeutics
Nong, S., Han, X., Xiang, Y., Qian, Y., Wei, Y., Zhang, T., Tian, K., Shen, K., Yang, J., & Ma, X. (2023) · MedComm · doi:10.1002/mco2.218 · Cited by 287
Fueling the Cell Division Cycle
Salazar-Roa, M., & Malumbres, M. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2016.08.009 · Cited by 268
Obesity and hyperinsulinemia drive adipocytes to activate a cell cycle program and senesce
Li, Q., Hagberg, C. E., Silva Cascales, H., Lang, S., Hyvönen, M. T., Salehzadeh, F., Chen, P., Alexandersson, I., Terezaki, E., Harms, M. J., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01501-8 · Cited by 178
Metadata
- Authors
- Lagarrigue, S., Lopez-Mejia, I. C., Denechaud, P.-D., Escoté, X., Castillo-Armengol, J., Jimenez, V., Chavey, C., Giralt, A., Lai, Q., Zhang, L., Martinez-Carreres, L., Delacuisine, B., Annicotte, J.-S., Blanchet, E., Huré, S., Abella, A., Tinahones, F. J., Vendrell, J., Dubus, P., Bosch, F., Kahn, C. R., & Fajas, L.
- Venue
- Journal of Clinical Investigation
- Published
- 2015-12-14
- Volume
- 126
- Issue
- 1
- Pages
- 335-348
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2212034801
- Cited by
- 76
- References
- 17
- FWCI
- 5.05
- Type
- journal article
- Language
- en
- Status
- Retracted
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CDK4 is an essential insulin effector in adipocytes. https://app.cochat.ai/papers/10.1172/jci81480
- The paper
- Lagarrigue, S., Lopez-Mejia, I. C., Denechaud, P.-D., Escoté, X., Castillo-Armengol, J., Jimenez, V., Chavey, C., Giralt, A., Lai, Q., Zhang, L., Martinez-Carreres, L., Delacuisine, B., Annicotte, J.-S., Blanchet, E., Huré, S., Abella, A., Tinahones, F. J., Vendrell, J., Dubus, P., . . . Fajas, L. (2015). CDK4 is an essential insulin effector in adipocytes. Journal of Clinical Investigation. https://doi.org/10.1172/jci81480
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.